Introduction
Compounded GLP-1 products are not FDA-approved and are not pre-reviewed by FDA for safety, effectiveness, or quality. The key questions are the exact active ingredient, dosage form, formulation, dispensing pharmacy, written instructions, and current FDA status.
A familiar drug name alone is not enough to establish equivalence with an approved product.
How compounded products differ from approved drugs
FDA-approved semaglutide and tirzepatide products undergo premarket review. Compounded versions do not. FDA states that compounded drugs are not reviewed for safety, effectiveness, or quality before they are marketed, which is why an approved pen label cannot automatically be applied to a compounded product.
Current telehealth prices and providers
These rows come from Telehealth Ledger's canonical catalog. A low headline price only ranks when medication is included and the continuing or prepaid basis is comparable.
Embody
Compounded semaglutide injection · Weekly subcutaneous injection · medication included
Price source · checked 22 August 2026CoreAge Rx
Compounded semaglutide injection · Injection · medication included
Price source · checked 18 August 2026HealthRX
Compounded Semaglutide · Weekly injection · medication included
Price source · checked 22 August 2026SnagRX
Compounded semaglutide injection · Weekly subcutaneous injection · medication included
Price source · checked 22 August 2026Telos RX
Compounded Semaglutide · Weekly injection · medication included
Price source · checked 22 August 2026Showing the 5 lowest comparable published prices from 15 eligible providers. The complete comparison includes every current catalog row.
- He & She MD: $149/mo effective • $447 prepaid every 3 monthsMedication included as published
- He & She MD: $139/mo effective • $834 prepaid every 6 monthsMedication included as published
- SkinnyRx: From $199/mo • exact renewal price depends on the selected planMedication included as published
Telos RX
Microdosed Tirzepatide · Weekly injection · medication included
Price source · checked 2 September 2026Embody
Compounded tirzepatide injection · Weekly subcutaneous injection · medication included
Price source · checked 22 August 2026GobyMeds
Compounded Tirzepatide Starter Plan · Weekly injection · medication included
Price source · checked 2 September 2026CoreAge Rx
Compounded tirzepatide injection · Injection · medication included
Price source · checked 18 August 2026SnagRX
Compounded tirzepatide injection · Weekly subcutaneous injection · medication included
Price source · checked 22 August 2026Showing the 5 lowest comparable published prices from 13 eligible providers. The complete comparison includes every current catalog row.
- He & She MD: $209/mo effective • $627 prepaid every 3 monthsMedication included as published
- He & She MD: $199/mo effective • $1,194 prepaid every 6 monthsMedication included as published
- SkinnyRx: From $299/mo • exact renewal price depends on the selected planMedication included as published
Eligibility, prescribed quantity, state availability, pharmacy fulfillment, shipping, supplies, and follow-up can change the final cost. Unknown fields remain unknown.
What to verify on the product and prescription
Verify the active ingredient, dosage form, formulation, dispensing pharmacy, prescriber, written instructions, and contact route for an error or reaction. FDA has described dosing errors linked to varying containers and concentrations. This page does not provide vial-volume, syringe-unit, reconstitution, or conversion instructions.
| Decision point | What the cited evidence can answer |
|---|---|
| Exact product | Confirm the approved indication, route, and formulation |
| Outcome evidence | Keep direct trials separate from indirect study comparisons |
| Practical fit | Review safety history, other medicines, follow-up, and access |
Why formulation and FDA policy matter
FDA has raised concerns about some semaglutide and tirzepatide salt forms and products with added ingredients. Shortage-related compounding policies and bulk-substance decisions can also change. Check current FDA materials before making an approval, quality, availability, or equivalence claim about a specific offer.
Ask verification questions
Verify the active ingredient, formulation, dispensing pharmacy, source documentation, written instructions, and who to contact about an error or reaction.
| Question | Evidence-based check |
|---|---|
| Exact product | Confirm the approved product, formulation, and labeled indication |
| Evidence | Keep direct trials separate from indirect comparisons |
| Access | Verify provider terms and price basis independently |
Regulatory status changes
Shortage resolution, enforcement discretion, and bulks-list policy are time-sensitive. Recheck FDA sources before publication and before commercial claims.
Do not turn this into a dosing guide
This page excludes vial math, syringe units, reconstitution, dose conversion, and self-switching advice.
What the cited sources establish
FDA distinguishes compounded GLP-1 products from approved drugs because compounded products are not pre-reviewed for safety, effectiveness, or quality. FDA communications also describe variable containers, concentrations, salt forms, additives, and dosing errors. Those facts make formulation identity central rather than a technical footnote.
The strongest documentation is product-level: the prescription, dispensing-pharmacy identity, active ingredient, dosage form, and written instructions attached to the container. That record helps distinguish a clinical symptom question from a formulation or dispensing question. FDA communications can clarify the regulatory context, but they do not convert an unverified offer into an approved product or establish that its concentration and instructions match a pen label.
Marketing language can obscure the facts that matter most. A product can use a familiar ingredient name while differing in dosage form, concentration, container, additives, or instructions. Those details affect what a pharmacist can verify and what a clinician needs to know when assessing a reaction. The appropriate comparison starts with the dispense record and current FDA material, then states plainly where information about the exact preparation is unavailable.
Questions that change the next review
The pharmacy conversation should document the active ingredient, dosage form, formulation, dispensing pharmacy, written instructions, and contact path for a suspected error or reaction. Keeping the prescription and container information together helps the clinical and pharmacy teams resolve a product question without importing instructions from an approved pen.
If the prescription, container, pharmacy record, and written instructions do not identify the same formulation, resolve that discrepancy before using a comparison table or making a safety assumption.
Product details that still need verification
A particular pharmacy's quality, lawful compounding status, and bioequivalence to an approved drug require product-specific verification. This guide excludes vial-volume, syringe-unit, reconstitution, and conversion guidance. If product identity is unclear, the comparison claim should stop there.
Compounded does not mean FDA-approved or bioequivalent. FDA has described errors linked to varying containers and concentrations. FDA shortage and compounding policies can change. A low price does not verify quality or suitability. Compounded semaglutide and tirzepatide are not FDA-approved products, and FDA does not pre-review them for safety, effectiveness, or quality. Verify the prescriber, pharmacy, active ingredient, formulation, and current regulatory context, and do not use vial or unit conversions from a web article. The next step is a clinician-led review of the exact product and your situation.
Use the current product label and prompt clinical care for urgent symptoms or medication changes.
Common questions
- What does the evidence show about Compounded GLP-1s: Pharmacy, Formulation, FDA Status, and Questions to Ask?
- Compounded semaglutide and tirzepatide are not FDA-approved products, and FDA does not pre-review them for safety, effectiveness, or quality. Verify the prescriber, pharmacy, active ingredient, formulation, and current regulatory context, and do not use vial or unit conversions from a web article.
- Can I use this as dosing or switching advice?
- No. This page excludes personalized dosing, conversions, and self-directed treatment changes.
- What should I check before acting?
- Check the current product label, the exact formulation, and the plan with the prescribing clinician.
- Why are labels named so often?
- Products can share an ingredient while having different approved uses, formulations, warnings, and evidence.
Use evidence to improve the next clinical conversation
Compounded semaglutide and tirzepatide are not FDA-approved products, and FDA does not pre-review them for safety, effectiveness, or quality. Verify the prescriber, pharmacy, active ingredient, formulation, and current regulatory context, and do not use vial or unit conversions from a web article. The next step is a clinician-led review of the exact product and your situation.
Sources
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting compounded GLP-1 pharmacy and formulation.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting compounded GLP-1 pharmacy and formulation.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting compounded GLP-1 pharmacy and formulation.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting compounded GLP-1 pharmacy and formulation.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting compounded GLP-1 pharmacy and formulation.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting compounded GLP-1 pharmacy and formulation.
Refresh triggers
- A new FDA label or Medication Guide
- A new major clinical-trial publication
- An ADA or AGA guideline update
- A material change to the verified provider registry